CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 130 enrolled
Drug / intervention
olmesartan medoxomil +1 moredrug
Likely dose
Olmesartan medoxomil oral tablets, once daily for up to 12 weeks; Losartan oral tablets, once daily for up to 12 weeksAI-extracted
Key inclusion· 2
  • ✓Diastolic blood pressure 95–114 mm Hg (inclusive)
  • ✓No participation in any clinical trial in the past 3 months
Key exclusion· 6
  • ✕Secondary hypertension
  • ✕Malignant hypertension
  • ✕Severe arterial hypertension
  • ✕Significant cardiovascular disease

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00857285
NCT00857285Phase 3Completed
CompareCT.gov

A Multi-center, Double Blind, Efficacy, and Safety Study of the Oral Angiotensin II Receptor Blocker "Olmesartan Medoxomil" Versus "Losartan" in Patients With Mild to Moderate Essential Hypertension

Daiichi Sankyo·interventional·Posted Mar 6, 2009·Updated Jul 23, 2009

In Brief

A Phase 3 clinical trial evaluating olmesartan medoxomil and losartan potassium for Essential Hypertension. Completed, enrolled 130 participants across 3 sites.

Detailed Summary

The purpose of this study is to determine the efficacy and safety of oral administration of olmesartan medoxomil compared to losartan in subjects with mild to moderate hypertension.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEssential Hypertension
CountriesTaiwan
CollaboratorsDaiichi Sankyo Taiwan Ltd.

Timeline

Phase 3CompletedFinished
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 6, 2009
Enrollment StartMay 1, 2002
Primary CompletionAug 1, 2003
Study CompletionSep 1, 2003
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 17.3 years ago

Interventions

olmesartan medoxomildrug

olmesartan medoxomil oral tablets, once daily for up to 12 weeks

losartan potassiumdrug

losartan oral tablets, once daily for up to 12 weeks